VALSECCHI, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 5.024
AS - Asia 2.463
EU - Europa 2.435
SA - Sud America 417
AF - Africa 62
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 10.426
Nazione #
US - Stati Uniti d'America 4.924
CN - Cina 1.015
SG - Singapore 747
PL - Polonia 487
UA - Ucraina 419
IT - Italia 380
BR - Brasile 353
DE - Germania 339
HK - Hong Kong 185
GB - Regno Unito 173
FI - Finlandia 167
VN - Vietnam 166
FR - Francia 139
IN - India 106
RU - Federazione Russa 105
IE - Irlanda 75
TR - Turchia 69
CA - Canada 55
BD - Bangladesh 32
CZ - Repubblica Ceca 26
MX - Messico 25
BE - Belgio 24
ID - Indonesia 22
JP - Giappone 20
SE - Svezia 20
SA - Arabia Saudita 19
IQ - Iraq 17
AR - Argentina 16
NL - Olanda 16
ZA - Sudafrica 16
AT - Austria 13
AU - Australia 12
ES - Italia 12
CO - Colombia 11
EC - Ecuador 11
NG - Nigeria 10
HU - Ungheria 9
PK - Pakistan 9
IR - Iran 8
KE - Kenya 8
MA - Marocco 8
VE - Venezuela 8
UZ - Uzbekistan 7
EG - Egitto 6
JO - Giordania 6
PH - Filippine 6
UY - Uruguay 6
A1 - Anonimo 5
CH - Svizzera 5
PY - Paraguay 5
TT - Trinidad e Tobago 5
AL - Albania 4
DZ - Algeria 4
EU - Europa 4
KG - Kirghizistan 4
PT - Portogallo 4
CL - Cile 3
HN - Honduras 3
IL - Israele 3
LT - Lituania 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
PA - Panama 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BH - Bahrain 2
CR - Costa Rica 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
SI - Slovenia 2
SV - El Salvador 2
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CU - Cuba 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
OM - Oman 1
PG - Papua Nuova Guinea 1
Totale 10.422
Città #
Fairfield 487
Warsaw 483
Ashburn 476
Singapore 391
Woodbridge 370
Jacksonville 314
Ann Arbor 260
Houston 240
Chandler 230
Beijing 192
New York 191
Hong Kong 185
San Jose 180
Seattle 179
Wilmington 178
The Dalles 174
Cambridge 167
Princeton 137
Helsinki 112
Nanjing 98
Los Angeles 81
Dearborn 80
Dublin 75
Brescia 74
Lauterbourg 64
Munich 63
Istanbul 58
Milan 56
Shenyang 50
Jinan 49
Des Moines 47
Nanchang 44
Moscow 43
Ho Chi Minh City 40
Chicago 38
Dallas 37
Boardman 36
Changsha 36
São Paulo 36
Tianjin 36
Hebei 34
Lancaster 34
Hanoi 33
San Francisco 29
Buffalo 28
Redondo Beach 27
Santa Clara 26
Orem 25
Shanghai 25
Turku 24
Jiaxing 23
London 23
Dong Ket 20
Rome 20
Guangzhou 19
Brussels 18
San Diego 18
Zhengzhou 18
Ningbo 17
Brooklyn 16
Chennai 16
Lanzhou 16
Montreal 16
Tokyo 16
Toronto 16
Brno 15
Atlanta 14
Manchester 14
Washington 14
Council Bluffs 13
Denver 13
Haikou 13
Frankfurt am Main 12
Norwalk 12
Phoenix 12
Hangzhou 11
Taizhou 11
Verona 11
Abuja 10
Mexico City 10
Olomouc 10
Boston 9
Charlotte 9
Jakarta 9
Kunming 9
Orange 9
Rio de Janeiro 9
Vienna 9
Belo Horizonte 8
Hefei 8
Johannesburg 8
New Delhi 8
Salvador 8
San Mateo 8
Stockholm 8
Taiyuan 8
Trieste 8
Da Nang 7
Fuzhou 7
Leawood 7
Totale 6.995
Nome #
Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways 320
New Copy Number Variations in Schizophrenia 318
Farmacoterapia antipsicotica e disturbi cognitivi. 246
The impairment of GABAergic pathway as one of the driver forces in the etiopathogenesis of schizophrenia: evidence from functional studies and gene-set enrichment analyses 232
A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme 209
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial. 204
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 198
Adult ADHD: Prevalence and Clinical Correlates in a Sample of Italian Psychiatric Outpatients 198
Factors Associated With Response and Resistance to Cognitive Remediation in Schizophrenia: A Critical Review 188
Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia 186
Comparison of quetiapine, olanzapine and risperidone in schizophrenia. 184
Looking through autistic features in schizophrenia using the PANSS Autism Severity Score (PAUSS) 184
-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study 183
Comparison of Quetiapine, Olanzapine, and Risperidone in Patients With Schizophrenia: Interim Results of a Randomised, Rater-blinded Study. 176
Psychomotor agitation in subjects hospitalized for an acute exacerbation of Schizophrenia 176
Effectiveness of Cognitive Remediation in Early Versus Chronic Schizophrenia: A Preliminary Report 175
Analysis of Copy Number Variations in Schizophrenia Italian Patients 173
Comparison of quetiapine (‘Seroquel’), olanzapine and risperidone in a randomized study in patients with schizophrenia. 173
A genome-wide pharmacogenomic study of patients with schizophrenia suggests that GRM7 mediates the effects of risperidone on positive symptoms 165
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis 164
Interim results of a randomised, rater-blinded study comparing quetiapine, olanzapine and risperidone in patients with schizophrenia. 163
At-risk gambling in patients with severe mental illness. Prevalence and associated features. 162
Autistic Symptoms in Schizophrenia: Impact on Internalized Stigma, Well-Being, Clinical and Functional Characteristics 159
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study 157
The role of the cytochine network in schizophrenia: an overview. 156
Well-being in patients with schizophrenia, mood and personality disorders attending psychiatric services in the community. A controlled study 156
Psychopharmacological treatment of cognitive deficits in Schizophrenia and mood disorders 152
A multimodal imaging study of never-medicated adults with schizophrenia 149
Patterns of Brain Structural Changes in First-Contact, Antipsychotic Drug-Naive Patients with Schizophrenia. 148
Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1 genes. 144
Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates 143
Additional Evidence for White Matter Damage in Never-Medicated Adults with Schizophrenia and Schizophreniform Disorder 142
Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients 142
Adult ADHD and sleep disorders: Prevalence, severity and predictors of sleep disorders in a sample of Italian psychiatric outpatients 142
Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. 141
Association study between schizophrenia and the AMPA genes GRIA1, GRIA2 AND GRIA4 139
Negative symptom severity at discharge from an index hospitalization and subsequent use of psychiatric care resources: A retrospective 1-year follow-up study on 450 patients with schizophrenia spectrum disorders 137
Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample 136
Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients 133
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. 132
Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. 131
Detection of high level of autozygosity in a group of Italian schizophrenia patients 130
Variables Associated With General Practitioners' Knowledge About and Diagnostic Skills for Schizophrenia 129
Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review 129
Immediate and 8-Month Impact of a Medical Educational Course for General Practitioners on Knowledge About Schizophrenia and Its Treatment: Results of a 3-Phase Study From Brescia, Italy. 128
Whole exome sequencing of schizophrenia patients with high level of autozygosity. 128
Manuale di clinica e riabilitazione psichiatrica. Dalle conoscenze teoriche alla pratica dei servizi di salute mentale. Vol. 2: Riabilitazione psichiatrica 128
Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia. 127
Relationship of IQ to neuropsychological tasks involving prefrontal cortex in schizophrenia. 126
Cerebrovascular accidents in elderly people treated with antipsychotic drugs. A systematic review 125
The factor structure analysis for the positive and negative syndrome scale (PANSS) in pharmacogenetics and pharmacogenomics studies. 124
New Copy Number Variations in Schizophrenia Italian Patients 123
Reduced fractional anisotropy of corpus callosum in first-contact, antipsychotic drug-naive patients with schizophrenia. 122
Whole exome sequencing of schizophrenia patients with high level of autozygosity. 121
Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition 117
Study of the genetic architecture behind mood disorders by whole exome sequencing on a large Italian pedigree 114
The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients 114
Mitochondrial DNA haplogroups and age at onset of schizophrenia 114
Panic disorder with and without comorbidity: data on epidemiology, course and treatment outcome. 111
Genome-Wide pharmacogenomics analysis of early antipsychotic (risperidone) response in patients with schizophrenia 109
Implementing cognitive rehabilitation interventions for schizophrenia patients in mental health services: Focus on Integrated Psychological Therapy (IPT) 109
Esperienze di switch a cariprazina in pazienti affetti da schizofrenia con ricorrenze 109
Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia 108
Paliperidone extended-release in the short- and long-term treatment of schizophrenia 106
Whole exome sequencing of schizophrenia patients with high level of autozygosity. 94
Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study 93
Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses 91
A miR-137–Related Biological Pathway of Risk for Schizophrenia Is Associated With Human Brain Emotion Processing 90
Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features 90
La comorbidità per uso di sostanze nei disturbi psicotici e nella schizofrenia. 83
Paliperidone palmitate in short- and long-term treatment of schizophrenia 76
Insight in cognitive impairment assessed with the Cognitive Assessment Interview in a large sample of patients with schizophrenia 72
THE FACTOR STRUCTURE FOR THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) IN PHARMACOGENETICS: 102T/C 5-HT2A POLYMORPHISM AND RESPONSE TO RISPERIDONE 72
Totale 10.628
Categoria #
all - tutte 46.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202159 0 0 0 0 0 0 0 0 0 0 0 59
2021/2022577 45 105 15 32 7 23 27 33 28 58 56 148
2022/2023639 86 9 6 68 46 176 4 67 96 11 40 30
2023/2024777 41 14 70 82 46 196 31 21 119 29 18 110
2024/20251.344 19 30 15 171 154 129 96 52 133 82 272 191
2025/20262.760 263 354 212 421 322 220 388 99 117 243 79 42
Totale 10.628